ES008：Anti-LILRB1 mAb to Fully Unleash Immunosuppression in TME
LILRB1 is the most broadly expressed member of the LILRB family. Activation of LILRB1 triggers immuno-suppressive signaling that interferes with LILRA-activated receptor-induced activation of multiple key immune cell responses. The blockade of LILRB1 enhances the functions of multiple immune cells, including NK cells, dendritic cells, monocytes/macrophages, T cells, and B cells.
High level of LILRB1 has been shown to correlate with reduced survival of cancer patients, and may contribute to PD-(L)1 resistance. Simultaneous blockade of LILRB1 and PD1 leads to greater T cell activation than blockade of either pathway alone. The key ligand of LILRB1, HLA-G, is highly expressed in cancers, making it a potential biomarker for anti-LILRB1 therapy.
ES008 is a potent LILRB1 blocker developed by Elpiscience. It can effectively promote NK cell–mediated destruction of HLA-G expressing tumor cells and synergize with CD47/SIRPα “don’t eat me” signal inhibitors in enhancing macrophage phagocytosis of tumor cells.
